Exercise-induced rhabdomyolysis and stress-induced malignant hyperthermia events, association with malignant hyperthermia susceptibility, and RYR1 gene sequence variations

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Carsana, Antonella ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; RYANODINE RECEPTOR 1; RYANODINE RECEPTOR;

CALCIUM CELL LEVEL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EXERCISE; EXERTIONAL RHABDOMYOLYSIS; GENE SEQUENCE; GENERAL ANESTHESIA; HUMAN; MALIGNANT HYPERTHERMIA; REVIEW; RHABDOMYOLYSIS; STRESS; SYSTEMATIC REVIEW; GENETIC VARIABILITY; GENETICS; INJURY; MECHANICAL STRESS; METABOLISM; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGICAL STRESS; SKELETAL MUSCLE;

BASE SEQUENCE; CALCIUM; DISEASE SUSCEPTIBILITY; GENETIC VARIATION; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE, SKELETAL; MUTATION, MISSENSE; PHYSICAL EXERTION; RHABDOMYOLYSIS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; STRESS, MECHANICAL; STRESS, PHYSIOLOGICAL;

EID: 84874897370     PISSN: 1537744X     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/531465     Document Type: Review

References (50)

1. Vanholder R., Sever M. S., Erek E., Lameire N., Rhabdomyolysis. Journal of the American Society of Nephrology 2000 11 8 1553 1561 2-s2.0-0033928804 (Pubitemid 30483474)
2. Warren J. D., Blumbergs P. C., Thompson P. D., Rhabdomyolysis: a review. Muscle & Nerve 2002 25 3 332 347 (Pubitemid 34203210)
3. Hackl W., Winkler M., Mauritz W., Sporn P., Steinbereithner K., Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced myolysis. British Journal of Anaesthesia 1991 66 1 138 140 2-s2.0-0026007610
4. Poels P. J. E., Joosten E. M. G., Sengers R. C. A., Stadhouders A. M., Veerkamp J. H., Benders A. A. G. M., In vitro contraction test for malignant hyperthermia in patients with unexplained recurrent rhabdomyolysis. Journal of the Neurological Sciences 1991 105 1 67 72 2-s2.0-0025870789 10.1016/0022-510X(91)90120-V
5. Figarella-Branger D., Kozak-Ribbens G., Rodet L., Aubert M., Borsarelli J., Cozzone P. J., Pellissier J. F., Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromuscular Disorders 1993 3 5-6 553 556 2-s2.0-0027763131 (Pubitemid 24050836)
6. Ogletree J. W., Antognini J. F., Gronert G. A., Postexercise muscle cramping associated with positive malignant hyperthermia contracture testing. American Journal of Sports Medicine 1996 24 1 49 51 2-s2.0-0030032595 (Pubitemid 26036327)
7. Ryan J. F., Tedeschi L. G., Sudden unexplained death in a patient with a family history of malignant hyperthermia. Journal of Clinical Anesthesia 1997 9 1 66 68 2-s2.0-0031080890 10.1016/S0952-8180(96)00207-3 (Pubitemid 27097328)
8. Weglinski M. R., Wedel D. J., Engel A. G., Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesthesia and Analgesia 1997 84 5 1038 1041 2-s2.0-0030909759 (Pubitemid 27197664)
9. Köchling A., Wappler F., Winkler G., Esch J. S. A., Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia. Anaesthesia and Intensive Care 1998 26 3 315 318 2-s2.0-2642639625 (Pubitemid 28251928)
10. Wappler F., Fiege M., Steinfath M., Agarwal K., Scholz J., Singh S., Matschke J., Schulte Esch J., Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001 94 1 95 100 2-s2.0-0035171073 (Pubitemid 32055184)
11. Campbell I. T., Ellis F. R., Evans R. T., Mortimer M. G., Studies of body temperature, blood lactate, cortisol and free fatty acid levels during exercise in human subjects susceptible to malignant hyperpyrexia. Acta Anaesthesiologica Scandinavica 1983 27 5 349 355 2-s2.0-0020644518 (Pubitemid 13015659)
12. Green J. H., Ellis F. R., Halsall P. J., Thermoregulation, plasma catecholamine and metabolite levels during submaximal work in individuals susceptible to malignant hyperpyrexia. Acta Anaesthesiologica Scandinavica 1987 31 2 122 126 2-s2.0-0023155495 (Pubitemid 17021478)
13. Tobin J. R., Jason D. R., Challa V. R., Nelson T. E., Sambuughin N., Malignant hyperthermia and apparent heat stroke. Journal of the American Medical Association 2001 286 2 168 169 2-s2.0-0034946063 (Pubitemid 32640845)
14. Nishio H., Sato T., Fukunishi S., Tamura A., Iwata M., Tsuboi K., Suzuki K., Identification of malignant hyperthermia-susceptible ryanodine receptor type 1 gene (RYR1) mutations in a child who died in a car after exposure to a high environmental temperature. Legal Medicine 2009 11 3 142 143 2-s2.0-63249092411 10.1016/j.legalmed.2008.12.004
15. Groom L., Muldoon S. M., Tang Z. Z., Identical de novo mutation in the RYR1 gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families. Anesthesiology 2011 115 5 938 945 10.1097/ALN. 0b013e3182320068
16. Davis M., Brown R., Dickson A., Horton H., James D., Laing N., Marston R., Norgate M., Perlman D., Pollock N., Stowell K., Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. British Journal of Anaesthesia 2002 88 4 508 515 2-s2.0-18344393048 10.1093/bja/88.4.508 (Pubitemid 34285200)
17. Bandschapp O., Girard T., Malignant hyperthermia. Swiss Medical Weekly 2012 142, article w13652
18. Ellis F. R., Halsall P. J., Ording H., A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. British Journal of Anaesthesia 1984 56 11 1267 1269 2-s2.0-0021149183
19. Larach M. G., Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesthesia & Analgesia 1989 69 4 511 515
20. Weiss R. G., O'Connell K. M. S., Flucher B. E., Allen P. D., Grabner M., Dirksen R. T., Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. American Journal of Physiology-Cell Physiology 2004 287 4 C1094 C1102 2-s2.0-4544330774 10.1152/ajpcell.00173.2004 (Pubitemid 39238334)
21. Pirone A., Schredelseker J., Tuluc P., Gravino E., Fortunato G., Flucher B. E., Carsana A., Salvatore F., Grabner M., Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Ca v α 1S- subunit. American Journal of Physiology 2010 299 6 C1345 C1354 2-s2.0-78649658370 10.1152/ajpcell.00008.2010
22. 2+ channel and the type 1 ryanodine receptor. Proceedings of the National Academy of Sciences 2012 109 20 7923 7928
23. Ferrer-Costa C., Gelpí J. L., Zamakola L., Parraga I., de la Cruz X., Orozco M., PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics 2005 21 14 3176 3178 2-s2.0-25144496606 10.1093/bioinformatics/bti486 (Pubitemid 41418475)
24. Ng P. C., Henikoff S., SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Research 2003 31 13 3812 3814 2-s2.0-0043122919 10.1093/nar/gkg509 (Pubitemid 37442253)
25. Ramensky V., Bork P., Sunyaev S., Human non-synonymous SNPs: server and survey. Nucleic Acids Research 2002 30 17 3894 3900 2-s2.0-0036713510 (Pubitemid 35012462)
26. Wehner M., Rueffert H., Koenig F., Neuhaus J., Olthoff D., Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation. Clinical Genetics 2002 62 2 135 146 2-s2.0-0036705958 10.1034/j.1399-0004.2002.620206.x (Pubitemid 36372713)
27. Girard T., Treves S., Censier K., Mueller C. R., Zorzato F., Urwyler A., Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells. British Journal of Anaesthesia 2002 89 4 571 579 2-s2.0-0036794325 10.1093/bja/aef237 (Pubitemid 35153779)
28. Brinkmeier H., Krämer J., Krämer R., Iaizzo P. A., Baur C., Lehmann-Horn F., Rüdel R., Malignant hyperthermia causing Gly2435Arg mutation of the ryanodine receptor facilitates ryanodine-induced calcium release in myotubes. British Journal of Anaesthesia 1999 83 6 855 861 2-s2.0-0345440064
29. Yang T., Ta T. A., Pessah I. N., Allen P. D., Functional defects in six ryanodine receptor isoform-1 (RYR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. Journal of Biological Chemistry 2003 278 28 25722 25730 2-s2.0-0037815064 10.1074/jbc.M302165200 (Pubitemid 36835328)
30. Girard T., Cavagna D., Padovan E., Spagnoli G., Urwyler A., Zorzato F., Treves S., B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. Journal of Biological Chemistry 2001 276 51 48077 48082 2-s2.0-0035930557
31. 2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. Journal of Biological Chemistry 1997 272 42 26332 26339 2-s2.0-0030666554 10.1074/jbc.272.42.26332 (Pubitemid 27458847)
32. Sambuughin N., Nelson T. E., Jankovic J., Xin C., Meissner G., Mullakandov M., Ji J., Rosenberg H., Sivakumar K., Goldfarb L. G., Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families. Neuromuscular Disorders 2001 11 6-7 530 537 2-s2.0-0034892948 10.1016/S0960-8966(01)00202-4 (Pubitemid 32761795)
33. Zullo A., Klingler W., De Sarno C., Ferrara M., Fortunato G., Perrotta G., Gravino E., Noto R. D., Lehmann-Horn F., Melzer W., Salvatore F., Carsana A., Functional characterization of ryanodine receptor (RYR1) sequence variants using a metabolic assay in immortalized B-lymphocytes. Human Mutation 2009 30 4 E575 E590 2-s2.0-63749092250 10.1002/humu.20991
34. Fortunato G., Carsana A., Tinto N., Brancadoro V., Canfora G., Salvatore F., A case of discordance between genotype and phenotype in a malignant hyperthermia family. European Journal of Human Genetics 1999 7 4 415 420 2-s2.0-0032976804 10.1038/sj.ejhg.5200314 (Pubitemid 29261326)
35. Robinson R. L., Anetseder M. J., Brancadoro V., van Broekhoven C., Carsana A., Censier K., Fortunato G., Girard T., Heytens L., Hopkins P. M., Jurkat-Rott K., Klinger W., Kozak-Ribbens G., Krivosic R., Monnier N., Nivoche Y., Olthoff D., Rueffert H., Sorrentino V., Tegazzin V., Mueller C. R., Recent advances in the diagnosis of malignant hyperthermia susceptability: how confident can we be of genetic testing? European Journal of Human Genetics 2003 11 4 342 348 2-s2.0-0037688073 10.1038/sj.ejhg.5200964 (Pubitemid 36553493)
36. Loke J., Kraeva N., MacLennan D., Mutations in RYR1 gene associated with malignant hyperthermia and a non-anaesthetic phenotype. Canadian Journal of Anaesthesia 2007 54 Supplement 1 4609 10.1007/BF03020021
37. Capacchione J. F., Sambuughin N., Bina S., Mulligan L. P., Lawson T. D., Muldoon S. M., Exertional rhabdomyolysis and malignant hyperthermia in a patient with ryanodine receptor type 1 gene, L-type calcium channel α -1 subunit gene, and calsequestrin-1 gene polymorphisms. Anesthesiology 2010 112 1 239 244 2-s2.0-74049155852 10.1097/ALN.0b013e3181c29504
38. Brown R. L., Pollock A. N., Couchman K. G., Hodges M., Hutchinson D. O., Waaka R., Lynch P., McCarthy T. V., Stowell K. M., A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. Human Molecular Genetics 2000 9 10 1515 1524 2-s2.0-0343184068 (Pubitemid 30386706)
39. Sambuughin N., Capacchione J., Blokhin A., Bayarsaikhan M., Bina S., Muldoon S., The ryanodine receptor type 1 gene variants in African American men with exertional rhabdomyolysis and malignant hyperthermia susceptibility. Clinical Genetics 2009 76 6 564 568 2-s2.0-70749157377 10.1111/j.1399-0004.2009. 01251.x
40. Levano S., Vukcevic M., Singer M., Matter A., Treves S., Urwyler A., Girard T., Increasing the number of diagnostic mutations in malignant hyperthermia. Human Mutation 2009 30 4 590 598 2-s2.0-63749119748 10.1002/humu.20878
41. Carpenter D., Robinson R. L., Quinnel R. J., Genetic variation in RYR1 and malignant hyperthermia phenotypes. British Journal of Anaesthesia 2009 103 4 538 548 10.1093/bja/aep204
42. Ibarra C. A., Wu S., Murayama K., Minami N., Ichihara Y., Kikuchi H., Noguchi S., Hayashi Y. K., Ochiai R., Nishino I., Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology 2006 104 6 1146 1154 2-s2.0-33744959480 10.1097/00000542-200606000-00008 (Pubitemid 43852946)
43. Grievink H., Stowell K. M., Allele-specific differences in ryanodine receptor 1 mRNA expression levels may contribute to phenotypic variability in malignant hyperthermia. Orphanet Journal of Rare Diseases 2010 5 1, article 10 2-s2.0-77952300810 10.1186/1750-1172-5-10
44. Robinson R. L., Carpenter D., Halsall P. J., Epigenetic allele silencing and variable penetrance of malignant hyperthermia susceptibility. British Journal of Anaesthesia 2009 103 2 220 225 10.1093/bja/aep108
45. Zhou H., Brockington M., Jungbluth H., Monk D., Stanier P., Sewry C. A., Moore G. E., Muntoni F., Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies. American Journal of Human Genetics 2006 79 5 859 868 2-s2.0-33751094327 10.1086/508500 (Pubitemid 44763400)
46. Zhou H., Jungbluth H., Sewry C. A., Feng L., Bertini E., Bushby K., Straub V., Roper H., Rose M. R., Brockington M., Kinali M., Manzur A., Robb S., Appleton R., Messina S., D'Amico A., Quinlivan R., Swash M., Müller C. R., Brown S., Treves S., Muntoni F., Molecular mechanisms and phenotypic variation in RYR1 -related congenital myopathies. Brain 2007 130 8 2024 2036 2-s2.0-34547757463 10.1093/brain/awm096 (Pubitemid 47236611)
47. Chelu M. G., Goonasekera S. A., Durham W. J., Tang W., Lueck J. D., Riehl J., Pessah I. N., Zhang P., Bhattacharjee M. B., Dirksen R. T., Hamilton S. L., Heat- and anesthesia-induced malignant hyperthermia in an RYR1 knock-in mouse. FASEB Journal 2006 20 2 329 330 2-s2.0-33644882215 10.1096/fj.05-4497fje (Pubitemid 46671160)
48. Durham W. J., Aracena-Parks P., Long C., Rossi A. E., Goonasekera S. A., Boncompagni S., Galvan D. L., Gilman C. P., Baker M. R., Shirokova N., Protasi F., Dirksen R., Hamilton S. L., RYR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RYR1 knockin mice. Cell 2008 133 1 53 65 2-s2.0-41149142599 10.1016/j.cell.2008.02.042 (Pubitemid 351442994)
49. Lanner J. T., Georgiou D. K., Dagnino-Acosta A., AICAR prevents heat induced sudden death in RYR1 mutant mice independent of AMPK activation. Nature Medicine 2012 18 2 244 251 10.1038/nm.2598
50. Corona B. T., Hamilton S. L., Ingalls C. P., Effect of prior exercise on thermal sensitivity of malignant hyperthermia-susceptible muscle. Muscle and Nerve 2010 42 2 270 272 2-s2.0-77955151296 10.1002/mus.21715